A phase 1, open-label study to investigate the absorption, metabolism, excretion, and mass balance of [14C]pacritinib following a single oral dose in healthy male subjects.

Completed

• Conditions: Chronic Myeloproliferative Disorders; abnormal growth of blood cells in the bone marrow; Myeloproliferative disorders

• Registration Number: NL-OMON41159
• Lead Sponsor: CTI BioPharma Corporation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

Non-smoking men between 18 and 55 years of age (inclusive).

Exclusion Criteria

Any severe acute or chronic medical condition, psychiatric condition, or laboratory abnormality that in the Investigator's opinion may increase the risk associated with study participation or administration of study treatment, or interfere with the interpretation of study results (such as gastrointestinal surgical history or obstructive uropathy).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Absorption<br /><br>Metabolism<br /><br>Excretion<br /><br>Mass balance</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>